DK4025612T3 - Anti-fukosyl-gm1-antistoffer - Google Patents
Anti-fukosyl-gm1-antistofferInfo
- Publication number
- DK4025612T3 DK4025612T3 DK20767753.5T DK20767753T DK4025612T3 DK 4025612 T3 DK4025612 T3 DK 4025612T3 DK 20767753 T DK20767753 T DK 20767753T DK 4025612 T3 DK4025612 T3 DK 4025612T3
- Authority
- DK
- Denmark
- Prior art keywords
- fucosyl
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1912657.2A GB201912657D0 (en) | 2019-09-03 | 2019-09-03 | Binding members |
| PCT/EP2020/074441 WO2021043810A1 (en) | 2019-09-03 | 2020-09-02 | Anti-fucosyl-gm1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4025612T3 true DK4025612T3 (da) | 2026-02-02 |
Family
ID=68207228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20767753.5T DK4025612T3 (da) | 2019-09-03 | 2020-09-02 | Anti-fukosyl-gm1-antistoffer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12552876B2 (da) |
| EP (1) | EP4025612B1 (da) |
| JP (1) | JP7672395B2 (da) |
| KR (1) | KR20220054648A (da) |
| CN (1) | CN114729057B (da) |
| AU (1) | AU2020340691A1 (da) |
| BR (1) | BR112022003568A2 (da) |
| CA (1) | CA3150555A1 (da) |
| DK (1) | DK4025612T3 (da) |
| ES (1) | ES3060303T3 (da) |
| FI (1) | FI4025612T3 (da) |
| GB (1) | GB201912657D0 (da) |
| PT (1) | PT4025612T (da) |
| WO (1) | WO2021043810A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201910899D0 (en) * | 2019-07-31 | 2019-09-11 | Scancell Ltd | Binding members |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE121C (de) | 1877-08-10 | FISCHER & STIEHL in Essen | Verfahren zur Kühlung und Vorwärmung der Luft mit Hülfe der Erdwärme | |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| AU7757581A (en) | 1980-11-19 | 1982-05-27 | United Energy Technologies Inc. | Enhanced surface tubing |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| JPS5811808A (ja) | 1981-07-16 | 1983-01-22 | Niles Parts Co Ltd | 方位検出表示回路 |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4630115A (en) | 1983-05-09 | 1986-12-16 | The General Electric Company, P.L.C. | Cathode ray tube display device |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| WO1999015201A1 (en) * | 1997-09-25 | 1999-04-01 | Sloan-Kettering Institute For Cancer Research | Fucosyl gm1-klh conjugate vaccine against small cell lung cancer |
| US7854934B2 (en) * | 1999-08-20 | 2010-12-21 | Sloan-Kettering Institute For Cancer Research | Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof |
| US8383118B2 (en) * | 2005-12-08 | 2013-02-26 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| EP3197918A1 (en) | 2014-09-25 | 2017-08-02 | Bristol-Myers Squibb Company | Treatment of lung cancer using an anti-fucosyl-gm1 antibody |
| JP2024503379A (ja) * | 2021-01-08 | 2024-01-25 | ブリストル－マイヤーズ スクイブ カンパニー | 抗フコシルｇｍ１抗体を使用した組み合わせ療法 |
-
2019
- 2019-09-03 GB GBGB1912657.2A patent/GB201912657D0/en not_active Ceased
-
2020
- 2020-09-02 US US17/639,467 patent/US12552876B2/en active Active
- 2020-09-02 EP EP20767753.5A patent/EP4025612B1/en active Active
- 2020-09-02 ES ES20767753T patent/ES3060303T3/es active Active
- 2020-09-02 JP JP2022514457A patent/JP7672395B2/ja active Active
- 2020-09-02 CA CA3150555A patent/CA3150555A1/en active Pending
- 2020-09-02 KR KR1020227010391A patent/KR20220054648A/ko active Pending
- 2020-09-02 CN CN202080061945.8A patent/CN114729057B/zh active Active
- 2020-09-02 BR BR112022003568A patent/BR112022003568A2/pt unknown
- 2020-09-02 WO PCT/EP2020/074441 patent/WO2021043810A1/en not_active Ceased
- 2020-09-02 FI FIEP20767753.5T patent/FI4025612T3/fi active
- 2020-09-02 AU AU2020340691A patent/AU2020340691A1/en active Pending
- 2020-09-02 PT PT207677535T patent/PT4025612T/pt unknown
- 2020-09-02 DK DK20767753.5T patent/DK4025612T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114729057A (zh) | 2022-07-08 |
| WO2021043810A8 (en) | 2025-07-03 |
| AU2020340691A1 (en) | 2022-03-24 |
| JP7672395B2 (ja) | 2025-05-07 |
| KR20220054648A (ko) | 2022-05-03 |
| GB201912657D0 (en) | 2019-10-16 |
| ES3060303T3 (en) | 2026-03-25 |
| FI4025612T3 (fi) | 2026-01-30 |
| US20220267466A1 (en) | 2022-08-25 |
| EP4025612A1 (en) | 2022-07-13 |
| JP2022546762A (ja) | 2022-11-08 |
| BR112022003568A2 (pt) | 2022-05-24 |
| EP4025612B1 (en) | 2025-10-29 |
| CA3150555A1 (en) | 2021-03-11 |
| CN114729057B (zh) | 2024-09-03 |
| US12552876B2 (en) | 2026-02-17 |
| PT4025612T (pt) | 2025-12-30 |
| WO2021043810A1 (en) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102763158B9 (ko) | 최적화된 항tl1a 항체 | |
| IL272227A (en) | Anti-tigit antibodies | |
| IL269405A (en) | Anti-sirp alpha antibodies | |
| EP3822289A4 (en) | ANTI-SIRP-ALPHA ANTIBODIES | |
| MA52884A (fr) | Anticorps anti-il-11 | |
| MA53434A (fr) | Anticorps anti-tigit | |
| EP3794041C0 (en) | ANTI-MUC1 ANTIBODIES | |
| EP3950061A4 (en) | ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| EP3661558A4 (en) | ANTI-IL1RAP ANTIBODIES | |
| PT3606954T (pt) | Anticorpos anti-lag3 | |
| IL287035A (en) | Anti-ige antibodies | |
| EP3569709A4 (en) | ANTI-GPC3 ANTIBODIES | |
| EP3883970A4 (en) | ANTI-B7-H3 ANTIBODIES | |
| EP3941944A4 (en) | Claudin-6 bispecific antibodies | |
| EP3691447A4 (en) | ANTI-TRANSTHYRETINE ANTIBODY | |
| EP4081547A4 (en) | Novel anti-fgfr2b antibodies | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| CR20230573A (es) | ANTICUERPOS ANTI-SIRP-alfa | |
| EP3763743A4 (en) | BISPECIFIC ANTIBODY | |
| DK4214240T3 (da) | Anti-ccr8-antistoffer | |
| EP4081539A4 (en) | Novel anti-fgfr2b antibodies | |
| EP3831851A4 (en) | ANTI-BTLA ANTIBODIES | |
| EP3768724A4 (en) | NEW ANTI-PD-1 ANTIBODIES | |
| IL281594A (en) | Anti-klrg1 antibodies |